A multiple center, randomized, double blind, parallel group, multiple oral doses study to evaluate the pharmacokinetic and pharmacodynamic profiles of 150 mg and 300 mg of SPP100 [aliskiren] in Japanese patients with mild to moderate essential hypertension

Trial Profile

A multiple center, randomized, double blind, parallel group, multiple oral doses study to evaluate the pharmacokinetic and pharmacodynamic profiles of 150 mg and 300 mg of SPP100 [aliskiren] in Japanese patients with mild to moderate essential hypertension

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2007

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Essential hypertension
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 28 Nov 2007 Status change from recruiting to completed.
    • 12 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top